Achieve Life Sciences, Inc. - Common Shares (ACHV)
Competitors to Achieve Life Sciences, Inc. - Common Shares (ACHV)
Cybin Inc.
Cybin Inc. engages in the development of psychedelic pharmaceuticals, including the exploration of novel therapies for mental health conditions. Both Achieve Life Sciences and Cybin are focused on developing innovative treatments; however, Cybin specializes in psychedelic compounds, which it claims can offer rapid relief from depression and anxiety. This focus on a distinctive mechanism of action may give Cybin a competitive edge in the fast-evolving mental health landscape.
Field Trip Health
Field Trip Health is a company focused on psychedelic therapies and also operates clinics for psychedelic-assisted psychotherapy. While Achieve Life Sciences is solely focused on pharmacological solutions for smoking cessation, Field Trip’s integration of therapy and treatment might attract patients looking for holistic approaches. This could provide them a competitive advantage in offering comprehensive care.
MindMed
MindMed is involved in the development of psychedelic-inspired medicines, and they focus similarly on treating addiction and mental health disorders. While Achieve Life Sciences targets smoking cessation through a nicotine-based treatment, MindMed diversifies its approach with psychedelics to treat a wider range of disorders. MindMed’s extensive pipeline may offer it a competitive advantage in the broader mental health treatment landscape.
Sculptor Capital Management, Inc.
Sculptor Capital Management engages in investment management, including investments in biotechnology and pharmaceuticals. This company does not directly compete with Achieve Life Sciences in the development of therapeutic products but may fund or invest in similar biotechnology firms. Therefore, Sculptor could potentially support competition among biopharma firms, but it does not compete in the therapeutic market directly.
Sutro Biopharma
Sutro Biopharma develops drug conjugates and other biopharmaceutical products and has a focus that overlaps with parts of Achieve Life Sciences' development pipeline. While Sutro primarily develops cancer therapeutics, both companies aim to leverage innovative science to treat complex health issues. However, with a broader focus on oncology, Sutro is positioned with a competitive advantage in a specific sector of drug development that may be more lucrative.